AUS
NZ
UK
CA
USA
IND
.jpg)
Huron Consulting Group Inc. announced the election of Dr. L. Thomas Richards as a director, effective July 23, 2026. Richards brings a wealth of expertise in life sciences, healthcare innovation, and executive leadership, having served as Chair of WittKieffer and CEO of molecular diagnostics and molecular tools companies. He will participate on three board committees and is scheduled for re-election at Huron's 2027 Annual Meeting of Stockholders.
Key Points
- NASDAQ: HURN
- Dr. L. Thomas Richards appointed to Huron's Board of Directors on July 23, 2026, effective immediately
- Assigned to Nominating and Corporate Governance Committee, Finance and Capital Allocation Committee, and Technology and Information Security Committee
- Director compensation includes an $80,000 annual cash retainer, $7,500 committee retainers per committee, and a prorated $90,000 restricted stock grant vesting August 1, 2027
Professional Background and Expertise of Dr. L. Thomas Richards
Dr. L. Thomas Richards offers a diverse professional background encompassing healthcare, life sciences innovation, and executive leadership. He most recently served as Chair of WittKieffer, a leadership advisory and executive search firm focused on healthcare, higher education, and life sciences sectors. His career highlights a strong emphasis on emerging technologies and innovation-driven growth within the life sciences industry, aligning well with Huron's consulting focus.
Richards has held key operational leadership roles in life sciences, including Interim CEO of One BioMed, a molecular tools company, and CEO of TessArae, a molecular diagnostics firm. He has also acted as Senior Advisor to various life sciences technology companies such as Metis Genetics, One BioMed, and Nanomix, providing strategic guidance. His advisory roles extend to venture capital and private equity investors in the life sciences sector, offering insight into capital allocation and innovative healthcare business models.
Academic Medicine and Investment Banking Foundations
In addition to his industry experience, Richards has a solid foundation in academic medicine and investment banking. He practiced emergency medicine and was an assistant professor at Stanford University and the University of California, San Francisco. This clinical and scientific background enhances his credibility in healthcare consulting and understanding of operational challenges in medical and life sciences organizations.
Early in his career, Richards worked in mergers and acquisitions at Lazard Frères, UBS, and SG Cowen. This M&A expertise complements Huron's focus on strategy and transformation. He has served on the boards of Cowen Group, Inc., TessArae, and One BioMed, reflecting governance experience in both public and private companies within relevant sectors.
Educational Achievements and Board Involvement
Dr. Richards holds an M.D. from Harvard Medical School, an M.Phil. from the University of Sydney, and a B.A. from Yale University. He is board-certified in Emergency Medicine, underscoring his medical qualifications. These credentials support his role in healthcare and life sciences consulting at Huron.
He also serves on the boards of two non-profit organizations: The World Telehealth Initiative and the Surfrider Foundation, demonstrating his commitment to healthcare innovation and environmental causes. The disclosure confirms no arrangements or understandings influenced his election and that he has no material interests requiring disclosure under securities regulations.
Committee Roles and Governance Responsibilities
Upon his election on July 23, 2026, Dr. Richards was appointed to three key Huron board committees: the Nominating and Corporate Governance Committee, the Finance and Capital Allocation Committee, and the Technology and Information Security Committee. These assignments leverage his expertise in governance, financial strategy, and technology oversight.
His background in life sciences innovation and financial advisory aligns with the committees' responsibilities. Notably, his role on the Technology and Information Security Committee reflects his focus on technology-enabled companies and innovation-driven growth within the life sciences sector.
Director Compensation Details
Dr. Richards's compensation follows Huron's non-employee director pay structure outlined in the 2026 Annual Proxy Statement filed on March 20, 2026. He will receive an $80,000 annual cash retainer as a base, plus $7,500 for each committee assignment, totaling $22,500 for his three committee roles. This is in addition to the base retainer, compensating for his committee responsibilities.
Restricted Stock Grant and Prorated Compensation
Huron grants directors an annual restricted stock award valued at $180,000 at the annual meeting. Since Dr. Richards joined mid-year, his initial grant is prorated to $90,000. This restricted stock will be granted on August 1, 2026, vesting fully on August 1, 2027. His cash retainer is also prorated from his July 23, 2026 appointment date, ensuring fair compensation for his service period.
Term Length and Re-Election Plans
Dr. Richards will serve until Huron's 2027 Annual Meeting of Stockholders, where he will stand for re-election. This one-year initial term is standard for new public company directors. His appointment adds valuable expertise in life sciences, healthcare innovation, and technology to Huron's Board without altering its size or composition.
Investors will likely observe how Richards's background influences the Board's oversight of Huron's strategic direction and consulting services in life sciences and healthcare sectors.
Conflict of Interest and Related-Party Transaction Disclosures
The filing confirms no arrangements or understandings influenced Dr. Richards's election and that he holds no direct or indirect material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K. This assures shareholders that his appointment is based solely on merit and complies with governance and securities regulations.
While no current conflicts exist, any future transactions meeting disclosure thresholds would be reported accordingly, maintaining transparency and governance standards.
